Abstract
The risk for Candida infections in patients with diabetes mellitus (DM) is three times higher than in the general population. Despite a DM prevalence of 15.8% reported in Libya (2024), the laboratory identification and susceptibility testing of fungal infections in patients with DM are not routinely performed. This cross‐sectional study investigated the prevalence and antifungal drug resistance patterns of Candida species in the oral mucosa of Libyan patients with Type 2 DM. Oral samples were collected with a sterile cotton swab, and 182 Candida isolates were phenotypically identified using the API ID 32 C and VITEK 2 Compact systems. Isolates were screened for their susceptibility to fluconazole and five other antifungals using disk diffusion and VITEK AST‐YS07 cards. Statistically significant associations were found between Candida carriage and clinical presentation (p = 0.032), denture wearing (p = 0.025) and sex (p = 0.012). Although Candida albicans was the predominant species isolated (37.4%), the majority of isolates comprised non‐albicans Candida (NAC). Candida humicola and Candida dubliniensis coexisted with other Candida species. Most Candida species showed susceptibility or dose‐dependent susceptibility (DDS) to fluconazole with low resistance to the other antifungal drugs. Candida glabrata, Candida guilliermondii and Candida krusei were resistant to fluconazole, and multidrug resistance was observed in some C. albicans, C. dubliniensis and C. krusei isolates. Candida membranifaciens and Candida parapsilosis showed either DDS or resistance to fluconazole. The emerging resistance to second‐line antifungals requires the establishment of routine Candida identification and antifungal susceptibility testing to guide species‐specific treatment.
Keywords: antimicrobial surveillance, Candida prevalence, diabetes mellitus Type 2, drug resistance
1. Introduction
Diabetes mellitus (DM) comprises a group of disorders characterised by elevated levels of glucose in the blood and serious life‐threatening health conditions affecting the heart, eyes, kidneys and nerves [1]. As one of the most significant chronic diseases worldwide, its prevalence in 2022 was estimated at 830 million people [1]. Population growth, ageing, urbanisation and the rising incidence of obesity and physical inactivity have contributed to this increase, with > 3.4 million people estimated to have died as a result of DM in 2024 [2].
Type 2 diabetes mellitus (T2DM) or noninsulin‐dependent DM is associated with a sedentary and western lifestyle and represents approximately 90% of diagnosed DM cases, affecting mostly people who are middle‐aged and obese [3]. In Libya, the prevalence of DM stood at 15.8% in 2024, with this number estimated to increase to 1 million by 2050 [2]. These statistics are compounded by the obesity epidemic in Libya [4, 5]. Apart from obesity, risk factors such as family history of DM, hypertension and microvascular complications necessitate a Libyan national policy for the surveillance, prevention and control of diabetes and its complications [6], and one such complication is candidiasis, caused by several species of the genus Candida.
Candida exists in the human host as commensal organisms but may cause opportunistic fungal infections when the host homeostasis is disturbed. Candida infections of the oral cavity are common in patients with immunosuppression [7], and because of increased salivary glucose and xerostomia [8, 9], patients with DM are three times more likely to have Candida infections compared to the general population [10]. Candida pathogenicity is enhanced by the heightened availability of Candida receptors [11] in patients with DM, as well as the enzyme activity and biofilm formation of Candida strains [12].
Candida albicans and Candidozyma auris are listed as critical priority group members in the WHO Fungal Priority Pathogens List [13], with Candida tropicalis, Candida parapsilosis and Candida glabrata listed in the high‐priority group of fungal pathogens [13]. Therefore, regular surveillance and public health interventions are imperative. Increasing reports of antifungal resistance and the frequent finding of increased non‐albicans Candida (NAC) species highlight the need for regular epidemiologic studies to identify new species prevalence and antifungal profiles that may alter the diagnosis and treatment of candidiasis. This is particularly relevant on the African continent, where resources are often limited and exceeded by treatment needs [14].
Multidrug‐resistant candidiasis has increasingly been associated with hospital settings. Reports from several hospitals in Africa reveal differences in Candida species prevalence and antifungal drug resistance. In South Africa, the epidemiology of Candida species has changed over the past 20 years, with the prevalent species shifting from C. albicans to C. parapsilosis and outbreaks of C. auris reported in a tertiary hospital setting [15–17]. C. auris has also been identified in patients from distinct healthcare facilities in Nigeria [18]. In Algeria, environmental and patient screening in seven hospitals in Algiers reported that C. tropicalis was the most prevalent, followed by C. parapsilosis, C. albicans and C. glabrata [19], with seven cases of C. auris infection reported from an intensive care unit (ICU) outbreak in 2022 [20]. Studies from two hospitals in Cairo, Egypt, reported C. albicans prevalence, followed by C. tropicalis and C. parapsilosis, with no C. glabrata. Less common NAC species were reported in the order of Candida lusitaniae, Candida utilis and Candida kefyr [21], while among patients in a tertiary hospital in Cairo, > 80% of multidrug‐resistant Candida isolates were identified as C. auris [22]. C. albicans was also the most predominant species reported from Tunisia, followed by C. parapsilosis, C. tropicalis and C. glabrata, with an overall fluconazole resistance of 6.7% [23]. Fluconazole resistance has been associated with its widespread and indiscriminate use in Africa, with only 12 African countries having access to echinocandins [24]. In this challenging and dynamic epidemiological landscape, Libya faces its own challenges, and regular monitoring of antimicrobial‐resistant bacterial and fungal species is required.
The laboratory identification and susceptibility testing of fungal infections is not commonly performed in Libya, with patients treated empirically according to their clinical symptoms. Suspected oral Candida infections are treated with nystatin suspension or fluconazole, the most widely prescribed antifungal drug for localised and disseminated candidiasis [25, 26], with no accurate identification or susceptibility testing performed. Hence, the treatment of seemingly similar Candida infections is not always done with the appropriate class of antifungal. In addition, the antifungal armamentarium in Libya is limited, with only lipid‐associated amphotericin B, fluconazole, voriconazole and itraconazole being available [27, 28].
A review of the burden of invasive fungal infections in Arabic countries showed an absence of published data on the prevalence of invasive Candida infection in Libya [29]. Although recent reports of Candida prevalence in Libya pertaining to vaginal candidiasis and DM have emerged [30, 31], there is a paucity of studies pertaining to oral Candida carriage in Libyan patients, particularly in those with DM.
This cross‐sectional study was aimed at investigating the prevalence and antifungal drug resistance patterns of Candida species isolated from the oral mucosa of Libyan patients with T2DM.
2. Materials and Methods
2.1. Ethical Considerations
Ethical clearance and authorisation for sample collection for this project were granted by the Ethics Committee at the University of Western Cape, South Africa (Ethics Clearance 14/3/1).
Prior to sample collection, the reasons for and nature of the study were explained to the patients who willingly consented to participate by signing a consent form. The study complied with the Declaration of Helsinki and its amendments [32].
2.2. Sample Collection
Three hundred thirty (330) patients with T2DM from the Misrata Diabetes Centre, Misrata, Northwest Libya, participated in this study. Samples were collected by scraping the patients′ oral mucosa and tongue with a sterile cotton swab. No information was gathered regarding oral hygiene practices or feeding prior to sample collection.
2.3. Inclusion and Exclusion Criteria
Only adult patients (24–95‐year‐olds) previously diagnosed with T2DM were selected. Patients who had been on antifungal therapy 2 weeks prior to sample collection were excluded from the study.
2.4. Isolation and Identification of Candida Species
The collected oral swabs were taken to the medical microbiology laboratories at Misrata Central Hospital, cultured on Sabouraud dextrose agar (SDA, Cat. No. 84088, Merck, Darmstadt, Germany) and incubated at 37°C for 24 h. Agar plates showing no growth were reincubated for an additional 24 h before being discarded as negative. All isolated Candida strains were stored at −80°C in Pro‐Lab Microbank microbial preservation vials (Cat. No. PL.170/M, Pro‐Lab, Canada) and SDA slants in 2.5 mL Eppendorf tubes, allowing them to be revived as and when needed. Samples were transported from Libya in these frozen preservation vials to the Maternal Endogenous Infections Studies (MenIS) Research Laboratories at the Department of Medical Biosciences, University of the Western Cape, South Africa, for characterisation.
Phenotypic screening for Candida species was achieved using conventional methods (microscopy, gram staining and the germ tube test). Isolates were presumptively identified to species level by streaking pure colonies on Fluka chromogenic Candida identification agar (Cat. No. 94382, Merck, Darmstadt, Germany) and Oxoid chromogenic Candida agar (Cat. No. CM1002A, Oxoid, Hampshire, United Kingdom), according to the manufacturers′ instructions. Species identification was confirmed using the VITEK 2 Compact system (bioMérieux, Marcy l′Étoile, France), an automated miniaturised microdilution system for routine clinical laboratory identification, and sensitivity testing was achieved with the YST test kit for yeasts (Cat. No. 21343, bioMérieux, Marcy l′Étoile, France). Isolates that could not be identified with the VITEK system were identified by biochemical testing using the API ID 32 C system (bioMérieux, Marcy l′Étoile, France), which conducts 29 assimilation tests and includes a colorimetric test for easy interpretation of results.
Nine Candida type strains were used as quality control organisms for the species identification and antifungal drug susceptibility testing, namely, C. albicans (ATCC 90028 and NCPF 3281), C. tropicalis (ATCC 950), Candida dubliniensis (NCPF 3949a), C. glabrata (ATCC 26512), Candida krusei (ATCC 2159), C. parapsilosis (ATCC 22019), C. kefyr (ATCC 4135) and C. lusitaniae (ATCC 3449). The nine Candida type strains were matched to the exact identification with the API ID 32 C and VITEK 2 Compact systems.
2.5. Antifungal Drug Susceptibility Testing
2.5.1. Agar Disk Diffusion
Isolates were screened for their susceptibility to fluconazole using disk diffusion by placing 25 μg fluconazole disks (Cat. No. X7148, Oxoid, Hampshire, United Kingdom) on yeast nitrogen base agar with glucose (YNBG) plates (Cat. No. 239210, Becton, Dickinson and Company, Swindon, United Kingdom) previously spread with a 0.5 McFarland standard suspension of the organisms (using a sterile cotton swab) and incubating at 37°C for 24 h. After incubation, the zones of inhibition around the fluconazole disks were measured from the edge of the disk to the edge of the susceptibility area, and the presence of microcolonies within the susceptibility zone noted and scored as previously described [33]. Samples with susceptibility areas < 7 mm with the presence of microcolonies were regarded as resistant, as well as samples with a microcolony score of > 2, while samples with susceptibility areas > 12 mm and a microcolony score of ≤ 2 were regarded as susceptible to fluconazole. Strains with a susceptibility area ranging from 7 to 12 mm were regarded as intermediate (or dose‐dependent) strains. Tests were done in triplicate. Microcolony and outer growth areas of random samples were stained and observed microscopically (Nikon SE, 1000x) for Candida species confirmation. These were subsequently grown on Oxoid and Fluka chromogenic Candida agars to confirm the species.
2.5.2. VITEK 2 Susceptibility Testing
VITEK AST‐YS07 cards (Cat. No. 414967, bioMérieux, Marcy l′Étoile, France) were used to confirm the species and antimicrobial sensitivity testing of the isolates. The susceptibility to six antifungal drugs was tested, namely, amphotericin B, caspofungin, micafungin, fluconazole, voriconazole and flucytosine.
Fresh 24‐h Candida subcultures were inoculated into sterile test tubes containing saline, and the density was adjusted to a 1.80–2.20 McFarland standard using the supplied VITEK nephelometer. A standardised concentration of the suspension in 0.45% saline was used to rehydrate the antifungal medium within the card according to the manufacturer′s instructions. Minimum inhibitory concentration (MIC) values were determined for each antifungal contained on the card according to the most updated Clinical and Laboratory Standards Institute (CLSI) interpretation given by the VITEK system. MICs were defined as the lowest concentrations that inhibited growth at 100%.
2.6. Statistical Analysis
Numbers (percentage) used to express qualitative data and quantitative data are presented by mean and standard deviation. Chi‐square was used to demonstrate the association between Candida species and patient data using the SPSS statistics software (SPSS Inc., Chicago, Illinois, United States) Version 24.0. p < 0.05 was considered significant.
3. Results
Of the 330 patients, 170 (51.5%) had Candida carriage, of whom 13 (7.6%) were diagnosed with active candidiasis and the remaining 92.3% with subclinical presentation. In total, 182 isolates were collected (12 patients carried two Candida species).
Of those with Candida carriage, 56% were female and 60% wore dentures, with most Candida‐positive participants located in the age range of ≥ 35 years (Table 1). Statistically significant associations were found between Candida carriage and patient clinical presentation (clinical vs. subclinical candidiasis, p = 0.032), denture wearing (higher Candida carriage in denture wearers, p = 0.025) and sex (higher Candida carriage in females, p = 0.012). No significant associations were found with smoking and age distribution (Table 1).
Table 1.
Patient variables associated with Candida carriage.
| Candida carriage | Dentures | Sex | Smoking | Age distribution (years) | ||||
|---|---|---|---|---|---|---|---|---|
| M | F | 15–34 | 35–64 | ≥ 65 | ||||
| Candida | 170 (51.5%) | 60 (60.6%) | 53 (42.4%) | 116 (56.6%) | 17 (38.6%) | 3 (75%) | 99 (48.5%) | 67 (54.9%) |
| No Candida | 160 (48.5%) | 39 (39.4%) | 72 (57.3%) | 89 (43.4%) | 27 (61.4%) | 1 (25%) | 105 (51.5%) | 55 (45.1%) |
| Total | 330 (100%) | 99 (100%) | 125 (100%) | 205 (100%) | 44 (100%) | 4 (100%) | 204 (100%) | 122 (100%) |
| p value | 0.025 | 0.012 | 0.073 | 0.339 | ||||
3.1. Frequency of Candida Species Isolated
Sixty‐eight of the 182 isolates (37.4%) were identified as C. albicans and 114 (62.6%) as NAC, including 42 (23%) C. dubliniensis, 26 (14.28%) Candida humicola, 20 (10.9%) C. glabrata (now known as Nakaseomyces glabratus, but to facilitate comparisons with other studies, we will retain the name C. glabrata within this manuscript), five (2.74%) C. krusei (now called Pichia kudriavzevii but referred to as C. krusei in this paper), five (2.74%) C. tropicalis, five (2.74%) C. kefyr, four (2.2%) Candida sake, two (1.1%) C. parapsilosis, two (1.1%) Candida magnoliae, one (0.55%) Candida guilliermondii, one (0.55%) Candida globosa and one (0.55%) Candida membranifaciens (Figure 1). None of the isolates were identified as C. auris.
Figure 1.
Distribution of Candida species identified by VITEK and API ID 32 C.
3.2. Antifungal Drug Susceptibility
3.2.1. Agar Disk Diffusion
One hundred fourteen (114), 31 and 37 of the 182 species were susceptible, intermediate (dose‐dependent susceptibility [DDS]) and resistant to fluconazole, respectively (Table 2). The majority of C. albicans, C. dubliniensis, C. humicola, C. kefyr, C. magnoliae, C. sake and C. tropicalis strains showed susceptibility or DDS to fluconazole, while C. glabrata, C. guilliermondii and C. krusei were resistant. C. membranifaciens and C. parapsilosis showed DDS or resistance to fluconazole.
Table 2.
Fluconazole susceptibility using agar disk diffusion and VITEK.
| Candida species | Susceptible, n (%) | Intermediate (dose-dependent susceptibility), n (%) | Resistant, n (%) | Total, n (%) | |
|---|---|---|---|---|---|
| C. albicans | ADD | 52 (76.4) | 12 (17.6) | 4 (5.8) | 68 (100) |
| VITEK | 64 (94.1) | 2 (2.9) | 2 (2.9) | 68 (100) | |
| C. dubliniensis | ADD | 33 (78.6) | 8 (19.0) | 1 (2.4) | 42 (100) |
| VITEK | 10 (76.9) | 1 (7.7) | 2 (15.3) | 13 (100) | |
| C. glabrata | ADD | 0 | 0 | 20 (100) | 20 (100) |
| VITEK | 0 | 20 (100) | 0 | 20 (100) | |
| C. globosa | ADD | 1 (100) | 0 | 0 | 1 (100) |
| VITEK | ND | ND | ND | ND | |
| C. guilliermondii | ADD | 0 | 0 | 1 (100) | 1 (100) |
| VITEK | ND | ND | ND | ND | |
| C. humicola | ADD | 20 (76.9) | 3 (11.5) | 3 (11.5) | 26 (100) |
| VITEK | ND | ND | ND | ND | |
| C. kefyr | ADD | 2 (40) | 3 (60) | 0 | 5 (100) |
| VITEK | 1 (50) | 1 (50) | 0 | 2 (100) | |
| C. krusei | ADD | 0 | 0 | 5 (100) | 5 (100) |
| VITEK | 0 | 0 | 5 (100) | 5 (100) | |
| C. magnoliae | ADD | 2 (100) | 0 | 0 | 2 (100) |
| VITEK | ND | ND | ND | ND | |
| C. membranifaciens | ADD | 0 | 1 (100) | 0 | 1 (100) |
| VITEK | ND | ND | ND | ND | |
| C. parapsilosis | ADD | 0 | 1 (50) | 1 (50) | 2 (100) |
| VITEK | 1 | 0 | 0 | 1 (100) | |
| C. sake | ADD | 2 (50) | 0 | 2 (50) | 4 (100) |
| VITEK | ND | ND | ND | ND | |
| C. tropicalis | ADD | 2 (40) | 3 (60) | 0 | 5 (100) |
| VITEK | 2 (50) | 2 (50) | 0 | 4 (100) | |
| ADD | 114 (62.6) | 31 (17.1) | 37 (20.3) | 182 (100) | |
| VITEK | 78 (69) | 26 (23) | 9 (8.0) | 113 (100) | |
Note: The bold data refers to the total numbers for ADD and VITEK.
Abbreviations: ADD, agar disk diffusion; ND, not detected (no interpretive breakpoints available).
3.2.2. VITEK
Because of limited resources, not all the isolates were subjected to VITEK analysis. Only species for which interpretative breakpoints are available and species showing DDS or resistance to fluconazole using ADD were included. Thus, 142 isolates (with only 13/42 C. dubliniensis species) were tested using VITEK. Seventy‐eight (78) isolates were categorised as susceptible to fluconazole by the VITEK 2 Compact system (Table 2), with 35 confirmed as either DDS (n = 26) or resistant (n = 9).
Regarding the control type strains, the intrinsically resistant C. glabrata was categorised as resistant to fluconazole by ADD and DDS by the VITEK system, and C. krusei was categorised as resistant by both ADD and VITEK. Other type strains were mostly susceptible to fluconazole by ADD and VITEK, except for C. tropicalis and C. kefyr, which expressed DDS.
Three species for which no interpretative breakpoints have yet been established on VITEK showed moderate to high fluconazole MIC values: three C. sake isolates between 4 and 8 μg/mL, one C. membranifaciens isolate with an MIC of 4 μg/mL and one C. guilliermondii isolate with an MIC of 2 μg/mL. Most of the Candida isolates demonstrated low resistance to the other antifungal drugs (Table 3).
Table 3.
Candida species susceptibility on VITEK.
| Antifungal drugs | Interpretation | C. albicans ( n = 68) | C. glabrata ( n = 20) | C. dubliniensis ( n = 13) | C. krusei ( n = 5) | C. tropicalis ( n = 4) | C. kefyr ( n = 2) | C. parapsilosis ( n = 1) |
|---|---|---|---|---|---|---|---|---|
| Amphotericin B | Susceptible | 68 | 18 | 13 | 4 | 4 | 2 | 1 |
| Intermediate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Resistant | 0 | 2 | 0 | 1 | 0 | 0 | 0 | |
| 5‐Flucytosine | Susceptible | 68 | 20 | 12 | 0 | 4 | 2 | 1 |
| Intermediate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Resistant | 0 | 0 | 1 | 5 | 0 | 0 | 0 | |
| Caspofungin | Susceptible | 68 | 0 | 13 | 5 | 4 | 2 | 1 |
| Intermediate | 0 | 20 | 0 | 0 | 0 | 0 | 0 | |
| Resistant | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Micafungin | Susceptible | 68 | 20 | 12 | 5 | 4 | 2 | 1 |
| Intermediate | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| Resistant | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Fluconazole | Susceptible | 64 | 0 | 5 | 0 | 2 | 1 | 1 |
| Intermediate | 2 | 20 | 0 | 0 | 2 | 1 | 0 | |
| Resistant | 2 | 0 | 3 | 5 | 0 | 0 | 0 | |
| Voriconazole | Susceptible | 67 | 20 | 7 | 5 | 4 | 2 | 1 |
| Intermediate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Resistant | 1 | 0 | 1 | 0 | 0 | 0 | 0 | |
Note: Only species for which interpretative breakpoints are available are shown. Intermediate = dose‐dependent susceptibility (DDS).
C. humicola (6/26 isolates) and 5/42 C. dubliniensis isolates coexisted with other Candida species in the oral cavity such as C. albicans (three isolates), C. krusei, C. kefyr (three isolates each) and C. magnoliae (Table 4).
Table 4.
Data of patients from whom two Candida species were isolated.
| Species susceptibility | Species susceptibility | Sex | Age | Dentures | Presentation | ||
|---|---|---|---|---|---|---|---|
| C. humicola | S | C. kefyr | I | F | 65 | No | Subclinical |
| S | C. kefyr | I | M | 76 | No | Subclinical | |
| S | C. krusei | R | F | 75 | No | Candidiasis | |
| I | C. dubliniensis | I | M | 62 | No | Subclinical | |
| R | C. tropicalis | I | M | 70 | Yes | Candidiasis | |
| S | C. albicans | S | F | 60 | No | Subclinical | |
| C. dubliniensis | I | C. membranifaciens | I | M | 66 | Yes | Subclinical |
| S | C. globosa | S | F | 62 | Yes | Subclinical | |
| S | C. parapsilosis | I | F | 58 | No | Subclinical | |
| S | C. albicans | S | M | 78 | No | Subclinical | |
| C. albicans | S | C. glabrata | R | M | 54 | Yes | Candidiasis |
| C. magnoliae | S | C. kefyr | I | F | 71 | Yes | Subclinical |
Note: The bold letters refer to the resistant organisms (that were only identified in patients with candidiasis).
Abbreviations: DDS, dose‐dependent susceptibility; I, intermediate; R, resistant; S, susceptible.
In patients who had two species of Candida, candidiasis was only apparent when one of the species showed resistance to fluconazole. Two of the three patients with candidiasis and who harboured two Candida species were denture wearers (Table 4).
4. Discussion
Accurate identification and susceptibility testing of fungal species are increasingly important, especially in the face of emerging resistance to commonly dispensed drugs. Differences in the treatment guidelines between various geographical areas can result in the emergence of strains resistant to different classes of antifungal agents. Because Candida infections are commonly associated with T2DM, regular monitoring of species prevalence is essential to ensure adequate treatment planning. This study highlights the prevalence of Candida species and their susceptibility profiles in a cross‐section of patients with T2DM in Misrata, Libya.
As in the study by Mussi et al. [34], several patients in our study presented with subclinical infection despite Candida carriage. Among the factors that predispose to candidiasis in patients with DM, this study considered sex, age, species frequency and denture wearing. Statistically significant associations were found between Candida carriage and clinical presentation, sex and denture wearing, with no significant associations with smoking and age distribution. Published reports show contradictions regarding the association between sex and Candida carriage [10]. Some show no significant differences in Candida carriage between the sexes [35], and others report a higher prevalence in females [36–38]. This may be attributed to hormonal changes [39].
Epidemiology studies suggest that distinct species predominate in different regions and in different body sites. Recent studies of patients with DM focused mainly on samples from the vagina, foot ulcers, gastrointestinal/urinary tracts and the oral cavity. A Libyan study of vaginal, toe and nail swabs from patients with DM [31] reported C. albicans prevalence, followed by C. tropicalis and C. glabrata. Species isolated from DM foot ulcers reported the predominating species as C. albicans (75%), C. lusitaniae (8%) and C. dubliniensis (5%) in Kenya [40]; C. parapsilosis (71.5%) and C. albicans (14.3%) in Iran [41]; C. albicans (13.2%) and a predominance of NAC (58.4%) comprising C. tropicalis, C. krusei, C. parapsilosis, Candida lipolytica, C. lusitaniae and C. guilliermondii in Iraq [38] and C. albicans (71.4%), C. tropicalis (21.4%) and C. glabrata (7.1%) in Egypt [42]. In Uganda [43], samples from the gastrointestinal tract showed that C. albicans (62.16%) was the predominant species, followed by C. glabrata (18.92%), C. tropicalis (8.11%), C. krusei (5.41%) and C. dubliniensis (5.41%), while a Nigerian study of midstream urine samples of patients with DM [44] reported isolates of C. albicans (45.7%), C. krusei (28.6%), C. glabrata (20%) and C. tropicalis (5.7%).
In this study of samples from the oral cavity, C. albicans showed the highest prevalence (37.4%), followed by C. dubliniensis (23%) and C. humicola (14.3%), while a recent Libyan study of oral samples showed C. albicans (66%), C. tropicalis (13.6%) and C. dubliniensis (5.1%) predominating, along with other NAC species [45]. Oral isolates from Slovakia [46] also showed C. albicans predominating (61.9%), followed by C. krusei (14.3%), Candida valida (9.5%) and C. glabrata, C. tropicalis and Candida intermedia (4.8% each).
Interestingly, our study identified a wide variety of Candida species in Libya, supporting a reported worldwide shift from C. albicans only to NAC prevalence. However, a review of Candida carriage and infection in patients with DM revealed a predominance of C. albicans and C. tropicalis, with fewer NAC infections detected in patients with DM than without DM [10]. When looking at neighbouring countries, studies from Egypt [21, 47] and Tunisia [23, 48] also reported C. albicans as the dominant species detected in fungal infections, followed by C. glabrata.
Overall, our results showed a low prevalence of drug resistance for most species present in this population and are in accordance with a recent Libyan study [45] that reported susceptibility or intermediate susceptibility to most of the antifungals tested. Multidrug resistance was observed in a C. albicans isolate (resistant to fluconazole and voriconazole), a C. dubliniensis isolate (resistant to fluconazole, voriconazole and 5‐flucytosine) and five C. krusei isolates (all resistant to fluconazole and 5‐flucytosine, with one of them also resistant to amphotericin B). The high resistance levels of all C. krusei (P. kudriavzevii) isolates to fluconazole and the intermediate susceptibility seen in C. glabrata (N. glabratus) are to be expected, since these species are intrinsically resistant to this drug. However, the resistance of C. krusei to flucytosine and amphotericin B is a cause for concern. Echinocandins and amphotericin B are considered optional empirical treatments for azole‐resistant infections. All tested C. glabrata isolates showed susceptibility to micafungin and intermediate susceptibility to caspofungin, with two of these isolates being resistant to amphotericin B.
To the best of our knowledge, this is the first time that widespread cross‐resistance of the intrinsically fluconazole‐resistant C. krusei and C. glabrata to a pyrimidine analogue and an echinocandin, respectively, is reported in Libyan patients. However, this finding should be interpreted with caution, since caspofungin testing for C. glabrata was reported to be unreliable [49] and echinocandin susceptibility was better determined by the VITEK micafungin result. The discrepancies reported for caspofungin have been attributed to an echinocandin phenomenon in which fungal species are completely susceptible at low concentrations but may subsequently grow in higher concentrations of the echinocandin. Because of this variability, the CLSI recommends that intermediate or resistant caspofungin results should be confirmed with a micafungin or anidulafungin test [50]. The finding of more than one Candida species colonising 12 of the patients in our study could also influence the transmission of resistance traits between Candida species and their increased pathogenicity in the oral biofilm. Co‐colonisation of Candida species was associated with three cases of candidiasis where one of the species showed resistance to fluconazole. In all three cases, the resistant species were C. glabrata, C. tropicalis and C. krusei. Other co‐colonisers such as C. dubliniensis and C. kefyr showed intermediate susceptibility. This could signal the exchange of resistance genes and subsequent predisposition of the host to further fungal colonisation and infection. The combined growth of Candida species can result in increased biofilm formation [51], allowing for metabolic cooperation within the polymicrobial biofilm and protection from the external environment, immune responses and antifungals [52, 53]. The aforementioned species were also detected in oral samples from Mexican patients with mixed Candida infections involving two or three species [54]. Mixed oral candidiasis occurs in approximately 10% of patients with T2DM [54], underscoring the importance of species identification and susceptibility to ensure effective treatment.
Two of the three patients with candidiasis in our study and who harboured two Candida species were denture wearers. Denture‐wearing patients with DM are twice as likely to present with Candida colonisation than nondenture wearers [10] because of the potential for Candida to adhere to acrylic surfaces and form biofilms.
The VITEK 2 Compact system has the advantage of being fully automated and allowing both fungal species identification and MIC determination rapidly and simultaneously. It also yields similar results to the antimicrobial susceptibility testing procedures developed by the CLSI [50, 55] and is available in most clinical microbiology laboratories. However, its accuracy in species identification is sometimes questionable [56]. For example, our comparison of API and VITEK species identification agreed for most species, but C. sake, C. globosa and C. membranifaciens were not correctly identified by VITEK, and 26 isolates identified as C. humicola by API were categorised as the yeast‐like fungus Stephanoascus ciferrii on VITEK.
VITEK susceptibility appeared to be more sensitive than ADD in some cases, with intermediate/resistant reports by ADD showing as susceptible/intermediate with VITEK. Inaccuracies in Candida susceptibility have previously been reported [37, 47]. In a study comparing broth microdilution (BM) assays with VITEK, major errors were reported for C. albicans susceptibility to fluconazole and voriconazole (12.5% and 4.2%, respectively), with 5.3% very major errors and 10.5% minor errors found for C. parapsilosis and 33.3% minor errors observed in C. tropicalis for fluconazole [57].
Similarly, VITEK antimicrobial susceptibility assays have been described as unacceptable for colistin [58] and tigecycline susceptibility [59] in studies of enteropathic gram‐negative bacilli, with BM and ADD, respectively, showing more reliable results. A preference for ADD over VITEK for susceptibility testing of unusual Enterobacteriaceae species has been reported previously [60].
Testing of uncategorised species by VITEK may result in an unidentified result or a misidentification, and false susceptibility reports may be detrimental to patients if inappropriate therapy is administered. Newer techniques for species identification have been proposed to eliminate the error of misidentification [61, 62]. However, these techniques are costly and not readily available within most regions on the African continent.
This study has several limitations: (i) The Candida identification to species level relied on phenotypic and biochemical testing. In the absence of molecular identification methods and because VITEK had not yet been updated to identify C. auris [63], we may have missed the identification of this important species. (ii) Newly described or rarer species of Candida are not included in the VITEK YST database. This, along with differences in sample size for the ADD and VITEK assays and the inability to determine critical breakpoints for all the species tested, prevented an accurate calculation of categorical agreement or error rates between the two assays. (iii) The clinical diagnosis of oral candidiasis was crude and limited to the presence of white lesions on the tongue or inner cheeks to differentiate between clinical infection and a carrier state. (iv) Confounding factors that may have contributed to Candida colonisation, such as oral hygiene practices and the use of chronic medications, were not considered in the collection and analysis of the data. (v) This is a cross‐sectional study conducted in one region (single‐centre setting) with a limited sample size and did not include a control group of patients without DM. We were therefore unable to compare the prevalence of NAC in patients with and without DM. (vi) The paucity of current data regarding the burden of disease as well as management and treatment practices in this region limits the comparison of our study with others in Libya to recommend effective treatment strategies.
Although previously excluded from global antimicrobial resistant programmes [64, 65], the escalating antifungal resistance has sparked a series of studies on alternative strategies to inhibit or eradicate Candida biofilms, and they show promise for the development of new and improved treatment methods [35, 66–69]. The emerging resistance to second‐line antifungals observed in this study requires further investigation incorporating the routine identification of infection‐causing Candida species, their antifungal resistance gene expression, along with continuing surveillance and implementation of species‐specific treatment in conjunction with the most recent diagnostic and treatment recommendations and within the context of One Health [70, 71].
Ethics Statement
Ethical clearance and authorisation for sample collection for this project were granted by the Ethics Committee at the University of Western Cape, South Africa (Ethics Clearance 14/3/1).
Disclosure
All authors read and approved the final manuscript. The manuscript is based on the thesis by one of the authors [72].
Conflicts of Interest
The authors declare no conflicts of interest.
Author Contributions
M.H.M.E. performed the laboratory isolation, identification and drug susceptibility of the Candida isolates, analysed the data and prepared the first draft of the manuscript. P.M.D.S.A. participated in the study′s design and coordination and contributed to the writing and revision of the manuscript. C.W.J.A. conceptualized the study and participated in its design, coordination, writing and revision of the manuscript. M.H.M.E. and P.M.D.S.A. contributed equally to this paper.
Funding
This study was funded by the Libyan Government (395/2013).
Acknowledgments
The authors would like to thank Dr. Abdoalmonaim Sanallah and Noriah Almahjoube at the Misrata Hospital for their assistance with sample collection, Carine Lang at bioMérieux for her assistance with this project and the food technology laboratory at the Cape Peninsula University of Technology for the use of the VITEK 2 Compact system. Our sincere gratitude is expressed to the patients who willingly participated in this study.
Esmaio, Mustafa H. M. , Abrantes, Pedro M. D. S. , Africa, Charlene W. J. , A Cross‐Sectional Study to Determine Candida spp. Carriage in Libyan Patients With Type 2 Diabetes, BioMed Research International, 2026, 5379778, 11 pages, 2026. 10.1155/bmri/5379778
Academic Editor: Mohsin Khurshid
Contributor Information
Charlene W. J. Africa, Email: cafrica@uwc.ac.za.
Mohsin Khurshid, Email: mohsin.mic@gmail.com.
Data Availability Statement
Data is provided within the manuscript and is available from the corresponding author upon reasonable request.
References
- 1. World Health Organization, Health Topic: Diabetes, 2024, Available at https://www.who.int/news-room/fact-sheets/detail/diabetes.
- 2. International Diabetes Federation, IDF Diabetes Atlas, 2025, 11th edition, [Online]. Available at: https://diabetesatlas.org.
- 3. Ahmad E., Lim S., Lamptey R., Webb D. R., and Davies M. J., Type 2 Diabetes, Lancet. (2022) 400, no. 10365, 1803–1820, 10.1016/S0140-6736(22)01655-5. [DOI] [PubMed] [Google Scholar]
- 4. Lemamsha H., Randhawa G., and Papadopoulos C., Investigating the Association Between Unhealthy Dietary Habits and Obesity Among Libyan Adults, International Journal of Environmental Research and Public Health. (2022) 19, no. 3, 10.3390/ijerph19031076, 35162100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. World Health Organization, Regional Office for the Eastern Mediterranean, 2023, Nutrition Country Profile, Available: https://iris.who.int/handle/10665/367693. [Google Scholar]
- 6. Allen L. N., Wild C. E. K., Loffreda G., Kak M., Aghilla M., Emahbes T., Bonyani A., Hatefi A., Herbst C., and El Saeh H. M., Non-Communicable Disease Policy Implementation in Libya: A Mixed Methods Assessment, PLOS Glob Public Health. (2022) 2, no. 11, e0000615, 10.1371/journal.pgph.0000615. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Rodrigues C. F., Rodrigues M. E., and Henriques M., Candida sp. Infections in Patients With Diabetes Mellitus, Journal of Clinical Medicine. (2019) 8, no. 1, 10.3390/jcm8010076, 30634716. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Mohammadi F., Javaheri M. R., Nekoeian S., and Dehghan P., Identification of Candida Species in the Oral Cavity of Diabetic Patients, Current Medical Mycology. (2016) 2, no. 2, 1–7, 10.18869/acadpub.cmm.2.2.4, 28681013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Tamai R. and Kiyoura Y., Candida Infections: The Role of Saliva in Oral Health - A Narrative Review, Microorganisms. (2025) 13, no. 4, 10.3390/microorganisms13040717, 40284554. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Rodríguez-Archilla A. and Piedra-Rosales C., Candida Species Oral Detection and Infection in Patients With Diabetes Mellitus: A Meta-Analysis, Iberoamerican Journal of Medicine. (2021) 3, no. 2, 115–121, 10.53986/ibjm.2021.0020. [DOI] [Google Scholar]
- 11. Casqueiro J., Casqueiro J., and Alves C., Infections in Patients With Diabetes Mellitus: A Review of Pathogenesis, Indian Journal of Endocrinology and Metabolism. (2012) 16, no. Supplement 1, S27–S36, 10.4103/2230-8210.94253, 22701840. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Nouraei H., Jahromi M. G., Jahromi L. R., Zomorodian K., and Pakshir K., Potential Pathogenicity of Candida Species Isolated From Oral Cavity of Patients With Diabetes Mellitus, BioMed Research International. (2021) 2021, 9982744, 10.1155/2021/9982744. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. World Health Organization, WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action, 2022, Available: https://www.who.int/publications-detail-redirect/9789240060241.
- 14. Boakye-Yiadom E., Odoom A., Osman A. H., Ntim O. K., Kotey F. C. N., Ocansey B. K., and Donkor E. S., Fungal Infections, Treatment and Antifungal Resistance: The Sub-Saharan African Context, Therapeutic Advances in Infectious Disease. (2024) 11, 20499361241297525, 10.1177/20499361241297525. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Shuping L., Mpembe R., Mhlanga M., Naicker S. D., Maphanga T. G., Tsotetsi E., Wadula J., Velaphi S., Nakwa F., Chibabhai V., Mahabeer P., Moncho M., Prentice E., Bamford C., Reddy K., Maluleka C., Mawela D., Modise M., Govender N. P., and for GERMS-SA, Epidemiology of Culture-Confirmed Candidemia Among Hospitalized Children in South Africa, 2012-2017, The Pediatric Infectious Disease Journal. (2021) 40, 730–737, 10.1097/INF.0000000000003151. [DOI] [PubMed] [Google Scholar]
- 16. Chibabhai V., Incidence of Candidemia and Prevalence of Azole-Resistant Candidemia at a Tertiary South African Hospital - A Retrospective Laboratory Analysis 2016-2020, Southern African Journal of Infectious Diseases. (2022) 37, no. 1, 10.4102/sajid.v37i1.326, 35284564. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Kekana D., Naicker S. D., Shuping L., Velaphi S., Nakwa F. L., Wadula J., Govender N. P., and for GERMS-SA1, Candida auris Clinical Isolates Associated With Outbreak in Neonatal Unit of Tertiary Academic Hospital, South Africa, Emerging Infectious Diseases. (2023) 29, no. 10, 2044–2053, 10.3201/eid2910.230181, 37735719. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Oladele R., Uwanibe J. N., Olawoye I. B., Ettu A. O., Meis J. F., and Happi C. T., Emergence and Genomic Characterization of Multidrug Resistant Candida auris in Nigeria, West Africa, Journal of Fungi. (2022) 8, no. 8, 10.3390/jof8080787, 36012776. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Megri Y., Arastehfar A., Boekhout T., Daneshnia F., Hörtnagl C., Sartori B., Hafez A., Pan W., Lass-Flörl C., and Hamrioui B., Candida tropicalis Is the Most Prevalent Yeast Species Causing Candidemia in Algeria: The Urgent Need for Antifungal Stewardship and Infection Control Measures, Antimicrobial Resistance and Infection Control. (2020) 9, no. 1, 10.1186/s13756-020-00710-z, 32264966. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Zerrouki H., Ibrahim A., Rebiahi S. A., Elhabiri Y., Benhaddouche D. E., de Groot T., Meis J. F., Rolain J. M., and Bittar F., Emergence of Candida auris in Intensive Care Units in Algeria, Mycoses. (2022) 65, no. 7, 753–759, 10.1111/myc.13470, 35546294. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Reda N. M., Hassan R. M., Salem S. T., and Yousef R. H. A., Prevalence and Species Distribution of Candida Bloodstream Infection in Children and Adults in Two Teaching University Hospitals in Egypt: First Report of Candida kefyr , Infection. (2023) 51, no. 2, 389–395, 10.1007/s15010-022-01888-7, 36018493. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Ahmed F., El-Kholy I. M., Abdou D. A. M., El-Mehalawy A. A., and Elkady N. A., Epidemiological and Microbiological Characterization of Candidozyma auris (Candida auris) Isolates From a Tertiary Hospital in Cairo, Egypt: An 18-Month Study, Scientific Reports. (2025) 15, no. 1, 32427, 10.1038/s41598-025-15302-3, 40940338. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Ben Brahim M., BenHamida-Rebai M., Haddad N., Tilouche L., Trabelsi A., and Ketata S., Surveillance of the Epidemiology and Antifungal Susceptibility of Invasive Candidiasis: A Retrospective Study From 2016 to 2020 in a Teaching Hospital in Sousse, Tunisia, Microbes and Infectious Diseases. (2024) 5, 347–358, 10.21608/mid.2023.222594.1562. [DOI] [Google Scholar]
- 24. Okoye C. A., Nweze E., and Ibe C., Invasive Candidiasis in Africa, What Is the Current Picture?, Pathogens and Disease. (2022) 80, no. 1, ftac012, 10.1093/femspd/ftac012. [DOI] [PubMed] [Google Scholar]
- 25. Rai A., Misra S. R., Panda S., Sokolowski G., Mishra L., Das R., and Lapinska B., Nystatin Effectiveness in Oral Candidiasis Treatment: A Systematic Review & Meta-Analysis of Clinical Trials, Life. (2022) 12, no. 11, 10.3390/life12111677, 36362833. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Xiao H., Miao Y., Liu L., Feng W., Liu S., Guo L., Guo X., Chen T., Hu B., Hu H., Xu F., Han L., Ren L., Li W., and Liu G., Clinical Characteristics of Central Nervous System Candidiasis due to Candida albicans in Children: A Single-Center Experience, BMC Infectious Diseases. (2022) 22, no. 1, 10.1186/s12879-022-07924-z, 36526986. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Kneale M., Bartholomew J. S., Davies E., and Denning D. W., Global Access to Antifungal Therapy and Its Variable Cost, Journal of Antimicrobial Chemotherapy. (2016) 71, no. 12, 3599–3606, 10.1093/jac/dkw325, 2-s2.0-84992456337, 27516477. [DOI] [PubMed] [Google Scholar]
- 28. Bongomin F., Ekeng B. E., Kwizera R., Salmanton-García J., Kibone W., van Rhijn N., Govender N. P., Meya D. B., Osaigbovo I. I., Hamer D. H., Oladele R., and Denning D. W., Fungal Diseases in Africa: Closing the Gaps in Diagnosis and Treatment Through Implementation Research and Advocacy, Journal of Medical Mycology. (2023) 33, no. 4, 101438, 10.1016/j.mycmed.2023.101438. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Kmeid J., Jabbour J. F., and Kanj S. S., Epidemiology and Burden of Invasive Fungal Infections in the Countries of the Arab League, Journal of Infection and Public Health. (2020) 13, no. 12, 2080–2086, 10.1016/j.jiph.2019.05.007, 2-s2.0-85067640036, 31248814. [DOI] [PubMed] [Google Scholar]
- 30. Abourghiba T. Y. and Alghadem Z. A., Prevalence of Vaginal Candidiasis Among Diabetic and Non-Diabetic Pregnant Women in Three Hospitals in Tripoli – Libya, Libyan Journal of Science. (2020) 23, no. 1, 115–119, 10.55276/ljs.v23i1.128. [DOI] [Google Scholar]
- 31. Abourghiba T. Y., Almsalati M. A., and Alghadem Z. A., Investigations of the Prevalence of Candida Infections in Diabetes Mellitus Patients in Tripoli, Libyan Journal of Science. (2022) 24, no. 1, 19–29, 10.55276/ljs.v24i1.183. [DOI] [Google Scholar]
- 32. Bibbins-Domingo K., Brubaker L., and Curfman G., The 2024 Revision to the Declaration of Helsinki: Modern Ethics for Medical Research, Journal of the American Medical Association. (2025) 333, no. 1, 30–31, 10.1001/jama.2024.22530. [DOI] [PubMed] [Google Scholar]
- 33. Yücesoy M., Güldaş N. Ş., and Yulu N., Disk Diffusion Method for Fluconazole Susceptibility Testing of Candida albicans Strains, Journal of Chemotherapy. (2001) 13, no. 2, 161–166, 10.1179/joc.2001.13.2.161, 2-s2.0-0035057692. [DOI] [PubMed] [Google Scholar]
- 34. Mussi M. C. M., Fernandes K. S., and Gallottini M. H. C., A Call for Further Research on the Relation Between Type 2 Diabetes and Oral Candidiasis, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology. (2022) 134, no. 2, 206–212, 10.1016/j.oooo.2022.02.009. [DOI] [PubMed] [Google Scholar]
- 35. Gamil Y., Hamed M. G., Elsayed M., Essawy A., Medhat S., Zayed S. O., and Ismail R. M., The Anti-Fungal Effect of Miconazole and Miconazole-Loaded Chitosan Nanoparticles Gels in Diabetic Patients With Oral Candidiasis - Randomized Control Clinical Trial and Microbiological Analysis, BMC Oral Health. (2024) 24, no. 1, 10.1186/s12903-024-03952-0, 38321454. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Chongtham U., Athokpam D. C., and Singh R. M., Isolation, Identification and Antifungal Susceptibility Testing of Candida Species: A Cross-Sectional Study From Manipur, India, Journal of Clinical and Diagnostic Research. (2022) 16, no. 4, DC09–DC14, 10.7860/JCDR/2022/55695.16248. [DOI] [Google Scholar]
- 37. Mohamed E., Abo Hagar A., and Hegazy E., Evaluation of ERG-11 Gene Expression in Azole Resistant Candida Isolates From Various Clinical Specimens in ICUs, Microbes and Infectious Diseases. (2022) 3, no. 1, 166–175, 10.21608/mid.2021.95727.1192. [DOI] [Google Scholar]
- 38. Al-Chalabi F. A., Abed R. M., Risan M. H., and Jabr Y. D., Prevalence of Candida albicans Infection Among Diabetic Foot Ulcer Patients in Al-Yarmouk Teaching Hospital, Medical Journal of Babylon. (2024) 21, no. Supplement 1, S137–S140, 10.4103/mjbl.mjbl_215_23. [DOI] [Google Scholar]
- 39. Sampath A., Weerasekera M., Gunasekara C., Dilhari A., Bulugahapitiya U., and Fernando N., A Sensitive and a Rapid Multiplex Polymerase Chain Reaction for the Identification of Candida Species in Concentrated Oral Rinse Specimens in Patients With Diabetes, Acta Odontologica Scandinavica. (2017) 75, no. 2, 113–122, 10.1080/00016357.2016.1265146, 2-s2.0-85006162957. [DOI] [PubMed] [Google Scholar]
- 40. Musyoki V. M., Mutai W., Ngugi N., Otieno F., and Masika M. M., Speciation and Antifungal Susceptibility of Candida Isolates From Diabetic Foot Ulcer Patients in a Tertiary Hospital in Kenya, Pan African Medical Journal. (2022) 41, 10.11604/pamj.2022.41.34.30815, 35382049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Moslemi A., Shokohi T., Salimi M., Faeli L., Davoodi L., Kashi Z., Abastabar M., Haghani I., Mayahi S., and Aghili S. R., Clinic-Mycological Spectrum of Candida Infection in Diabetic Foot Ulcers in a Tertiary Care Hospital, Current Medical Mycology. (2023) 9, no. 4, 9–16, 10.22034/cmm.2024.345165.1484. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Shalaby R. S., Gaafar M. M., El Basshar M. A., Soliman M. S., Yousry M. M., and Elmahdy Y. A., Clinical Study of Coexistence of Fungal Infections in Diabetic Foot Ulcers by 18s rRNA Gene Polymerase Chain Reaction, Open Access Maced Journal of Medical Sciences. (2023) 11, no. A, 36–40, 10.3889/oamjms.2023.9602. [DOI] [Google Scholar]
- 43. Oyom A. P., Okello E., Acam V., Aramo C., Mwambi B., Okiria J. C., and Oyet C., Prevalence and Antifungal Susceptibility of Gastrointestinal Candidiasis Among Diabetic Patients: A Cross-Sectional Study, African Journal of Laboratory Medicine. (2020) 9, no. 1, 10.4102/ajlm.v9i1.997, 33354526. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Sule H., Kumurya A. S., and Abdulmumin S., Candidiasis Among Diabetic Patients Attending Aminu Kano Teaching Hospital, Kano-Nigeria, World Journal of Biology. (2020) 2, no. 2, 10–15, 10.30574/wjbphs.2020.2.2.0024. [DOI] [Google Scholar]
- 45. Ramadan M. A., Mustafa L. S., Jaber M. A., and Ingafou M. S., Detection of Species Diversity in Oral Fungi Colonization and Anti-Fungal Susceptibility Among Non-Oral Habit Adult Patients, Research Journal of Pharmacy and Technology: RJPT. (2023) 16, no. 11, 10.52711/0974-360X.2023.00861. [DOI] [Google Scholar]
- 46. Černáková L., Líšková A., Lengyelová L., and Rodrigues C. F., Prevalence and Antifungal Susceptibility Profile of Oral Candida spp. Isolates From a Hospital in Slovakia, Medicina (Kaunas, Lithuania). (2022) 58, no. 5, 10.3390/medicina58050576. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Ismail M. G., Ali J. A., Abd El Haliem N. F., Abdel Wahab A. M., and Ghoraba N. M., Vitek 2 System for Identification and Susceptibility Testing of Candida Species With Detection of Fluconazole Resistant Genes, Jesus Rock of Ages Ministries. (2024) 5, no. 2, 157–165, 10.21608/jram.2024.307952.1259. [DOI] [Google Scholar]
- 48. Fathallah A., Chouaieb H., Saief M. B., Ismaïl S., Said M. B., Denning D. W., and in association with the Tunisian Society for Infectious Diseases (Société Tunisienne de Pathologie Infectieuse (STPI)), The Incidence and Prevalence of Serious Fungal Diseases in Tunisia, Journal of Medical Mycology. (2024) 34, no. 2, 101479, 10.1016/j.mycmed.2024.101479. [DOI] [PubMed] [Google Scholar]
- 49. Lim H. J., Shin J. H., Kim M. N., Yong D., Byun S. A., Choi M. J., Lee S. Y., Won E. J., Kee S. J., Kim S. H., and Shin M. G., Evaluation of Two Commercial Broth Microdilution Methods Using Different Interpretive Criteria for the Detection of Molecular Mechanisms of Acquired Azole and Echinocandin Resistance in Four Common Candida Species, Antimicrobial Agents and Chemotherapy. (2020) 64, no. 11, e00740, 10.1128/AAC.00740-20, 32900684. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. CLSI, Performance Standards for Antifungal Susceptibility Testing of Yeasts, 2020, 2nd edition, Clinical and Laboratory Standards Institute. [Google Scholar]
- 51. Abrantes P. M. D. S., Behardien K., and Africa C. W. J., Real-Time Assessment of Interspecies Candida Biofilm Formation, Open Microbiology Journal. (2022) 16, e187428582211230, 10.2174/18742858-v16-e221128-2022-26. [DOI] [Google Scholar]
- 52. Ramage G., Mowat E., Jones B., Williams C., and López-Ribot J., Our Current Understanding of Fungal Biofilms, Critical Reviews in Microbiology. (2009) 35, no. 4, 340–355, 10.3109/10408410903241436, 2-s2.0-70350557500. [DOI] [PubMed] [Google Scholar]
- 53. Pierce C. G., Vila T., Romo J. A., Montelongo-Jauregui D., Wall G., Ramasubramanian A., and Lopez-Ribot J. L., The Candida albicans Biofilm Matrix: Composition, Structure and Function, Journal of Fungi. (2017) 3, no. 1, 10.3390/jof3010014, 2-s2.0-85044587924. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Araiza J., Sánchez-Pedraza V., Carrillo A. K., Fernández-Samar D., Tejeda J., and Bonifaz A., Mixed Oral Candidiasis in Type 2 Diabetic Patients: Identification and Spectrum of Sensitivity, Biomédica. (2023) 43, 97–108, 10.7705/biomedica.6878. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. CLSI, Epidemiological Cutoff Values for Antifungal Susceptibility Testing, 2020, 3rd edition, Clinical and Laboratory Standards Institute. [Google Scholar]
- 56. Acosta-Mosquera Y., Tapia J. C., Armas-González R., Cáceres-Valdiviezo M. J., Fernández-Cadena J. C., and Andrade-Molina D., Prevalence and Species Distribution of Candida Clinical Isolates in a Tertiary Care Hospital in Ecuador Tested From January 2019 to February 2020, Journal of Fungi. (2024) 10, no. 5, 10.3390/jof10050304. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Lee H., Choi S. H., Oh J., Koo J., Lee H. J., Cho S., Shin J. H., Lee H. K., Kim S., Lee C. H., Kim Y. R., Sohn Y., Kim W. J., Ryu S. W., Sung G., and Kim J., Comparison of Six Antifungal Susceptibilities of 11 Candida Species Using the VITEK2 AST–YS08 Card and Broth Microdilution Method, Microbiology Spectrum. (2022) 10, e01253, 10.1128/spectrum.01253-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Fadana V., Thomas T., and von Knorring N., Retrospective Analysis of Vitek2 Performance Compared to Manual Broth Micro-Dilution for Colistin Susceptibility Testing of Acinetobacter baumannii Complex Isolates in South Africa, African Journal of Laboratory Medicine. (2022) 11, no. 1, 10.4102/ajlm.v11i1.1597. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Yin D., Guo Y., Li M., Wu W., Tang J., Liu Y., Chen F., Ni Y., Sun J., Zhang H., Zhao H., and Hu F., Performance of VITEK 2, E-Test, Kirby-Bauer Disk Diffusion, and Modified Kirby-Bauer Disk Diffusion Compared to Reference Broth Microdilution for Testing Tigecycline Susceptibility of Carbapenem-Resistant K. pneumoniae and A. baumannii in a Multicenter Study in China, European Journal of Clinical Microbiology & Infectious Diseases. (2021) 40, no. 6, 1149–1154, 10.1007/s10096-020-04123-z. [DOI] [PubMed] [Google Scholar]
- 60. Sohani Z. N., Lieu A., Bamba R., Patel M., Paul M., Yahav D., McDonald E. G., Lawandi A., and Lee T. C., Establishing Piperacillin-Tazobactam Susceptibility in Ceftriaxone Non-Susceptible Enterobacterales: Comparing Disk Diffusion, Etest, and VITEK 2 Automated Minimal Inhibitory Concentration Measurements vs. Broth Microdilution, Clinical Microbiology and Infection. (2025) 31, no. 4, 575–581, 10.1016/j.cmi.2024.11.031. [DOI] [PubMed] [Google Scholar]
- 61. Camp I., Spettel K., and Willinger B., Molecular Methods for the Diagnosis of Invasive Candidiasis, Journal of Fungi. (2020) 6, no. 3, 10.3390/jof6030101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62. Salem-Bango Z., Price T. K., Chan J. L., Chandrasekaran S., Garner O. B., and Yang S., Fungal Whole-Genome Sequencing for Species Identification: From Test Development to Clinical Utilization, Journal of Fungi. (2023) 9, no. 2, 10.3390/jof9020183, 36836298. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Ambaraghassi G., Dufresne P. J., Dufresne S. F., Vallières É., Muñoz J. F., Cuomo C. A., Berkow E. L., Lockhart S. R., and Luong M. L., Identification of Candida auris by Use of the Updated Vitek 2 Yeast Identification System, Version 8.01: a Multilaboratory Evaluation Study, Journal of Clinical Microbiology. (2019) 57, e00884, 10.1128/JCM.00884-19, 2-s2.0-85074047860. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64. Fisher M. C., Gurr S. J., Cuomo C. A., Blehert D. S., Jin H., Stukenbrock E. H., Stajich J. E., Kahmann R., Boone C., Denning D. W., Gow N. A. R., Klein B. S., Kronstad J. W., Sheppard D. C., Taylor J. W., Wright G. D., Heitman J., Casadevall A., and Cowen L. E., Threats Posed by the Fungal Kingdom to Humans, Wildlife, and Agriculture, MBio. (2020) 11, no. 3, 10.1128/mbio.00449-20, 32371596. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Rodrigues M. L. and Nosanchuk J. D., Fungal Diseases as Neglected Pathogens: A Wake-Up Call to Public Health Officials, PLoS Neglected Tropical Diseases. (2020) 14, no. 2, e0007964, 10.1371/journal.pntd.0007964, 32078635. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Sousa F., Ferreira D., Reis S., and Costa P., Current Insights on Antifungal Therapy: Novel Nanotechnology Approaches for Drug Delivery Systems and New Drugs From Natural Sources, Pharmaceuticals (Basel). (2020) 13, no. 9, 10.3390/ph13090248, 32942693. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67. Abdallah R. M. and Aref N. S., Curcumin Containing Soft Liner as an Alternative Treatment Modality for Oral Candidiasis, World Journal of Dentistry. (2021) 12, no. 6, 435–440, 10.5005/jp-journals-10015-1867. [DOI] [Google Scholar]
- 68. Soutome S., Otsuru M., Kawashita Y., Yoshimatsu M., Funahara M., Murata M., Ukai T., Umeda M., and Saito T., A Preliminary Study of Suppression of Candida Infection by Miconazole Mucoadhesive Tablets in Oral or Oropharyngeal Cancer Patients Undergoing Radiotherapy, Scientific Reports. (2022) 12, no. 1, 10188, 10.1038/s41598-022-14269-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69. Abrantes P. M. D. S., Stuurman K. C., Klaasen J. A., and Africa C. W. J., Monitoring of Candida Biofilm Inhibition by Galenia africana Using Real-Time Impedance-Based Technology, Current Medical Mycology. (2024) 10, 10.22034/cmm.2024.345240.1541, 40584603. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70. Barantsevich N. and Barantsevich E., Diagnosis and Treatment of Invasive Candidiasis, Antibiotics. (2022) 11, no. 6, 10.3390/antibiotics11060718. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71. Fisher M. C., Alastruey-Izquierdo A., Berman J., Bicanic T., Bignell E. M., Bowyer P., Bromley M., Brüggemann R., Garber G., Cornely O. A., Gurr S. J., Harrison T. S., Kuijper E., Rhodes J., Sheppard D. C., Warris A., White P. L., Xu J., Zwaan B., and Verweij P. E., Tackling the Emerging Threat of Antifungal Resistance to Human Health, Nature Reviews Microbiology. (2022) 20, no. 9, 557–571, 10.1038/s41579-022-00720-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72. Esmaio M. H., The Antifungal Effect of Salvadora persica and Euclea natalensis on Candida Isolates From Libyan Patients With Type 2 Diabetes Mellitus, 2018, Doctoral dissertation, University of the Western Cape, ResearchGate. https://www.researchgate.net/publication/325011654_The_antifungal_effect_of_Salvadora_persica_and_Euclea_natalensis_on_Candida_isolates_from_Libyan_patients_with_type_2_Diabetes_mellitus. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data is provided within the manuscript and is available from the corresponding author upon reasonable request.